NCT02786719 - High-Risk Neuroblastoma Chemotherapy Without G-CSF | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

February 5, 2019

Study Completion Date

February 5, 2019

Conditions

Neuroblastoma

Interventions

DRUG

Topotecan

CYCLE 1+2 (given by intravenous catheter daily for 5 days)

DRUG

Cyclophosphamide

CYCLE 1+2 (given by intravenous catheter daily for 5 days)

DRUG

Cisplatin

Cycle 3+5 (given daily x 4 days)

DRUG

Etoposide

Cycle 3+5 (given daily for 3 days)

DRUG

Vincristine

Cycle 4+6 (given daily for 3 days)

DRUG

Cyclophosphamide

Cycle 4+6 (given daily for 2 days)

DRUG

Doxorubicin

Cycle 4+6 (given daily for 3 days)

DRUG

Sargramostim

Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)

Trial Locations (2)

Texas Children's Hospital, Houston

Rady Children's Hospital, San Diego

All Listed Sponsors

lead

Baylor College of Medicine

OTHER